Summary & Overview
HCPCS J0205: Injection, Alglucerase, per 10 Units
HCPCS Level II code J0205 denotes the injectable agent alglucerase measured per 10 units and is used to bill for enzyme replacement therapy administration. This code matters nationally because alglucerase is a specialty biologic used to treat enzyme deficiency conditions, and accurate coding affects coverage, patient access, and reimbursement for high-cost therapies. Payers commonly involved in coverage decisions for this code include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will learn the clinical context for using J0205, the typical sites of service where alglucerase is administered, and the scope of payer coverage in a national setting. The publication summarizes common billing considerations, how this code fits into service lines for outpatient infusion and hospital-based administration, and what benchmarks and policy updates are relevant for stakeholders managing specialty infusion therapies. Data not available in the input are explicitly noted where applicable.
Billing Code Overview
HCPCS Level II code J0205 represents Injection, alglucerase, per 10 units. This code is used to report administration of alglucerase, an enzyme replacement therapy typically supplied and injected in measured unit quantities.
Service Type: Therapeutic injection / enzyme replacement therapy
Typical Site of Service: Outpatient infusion clinic or hospital outpatient department, and may also be used in specialized infusion centers where enzyme replacement therapies are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with Gaucher disease type 1 or another lysosomal storage disorder requiring enzyme replacement therapy. The patient presents to an outpatient infusion center or hospital outpatient department for scheduled intravenous administration of alglucerase. Prior to infusion, a registered nurse performs verification of identity, review of allergies and premedication orders, baseline vital signs, and checks of laboratory values (for example hemoglobin, platelet count, and liver function tests). The pharmacy compounds the dose in 10-unit increments based on the patient’s weight and the prescribed dosing regimen. The infusion is delivered via peripheral IV or tunneled central line over the institution’s recommended infusion time with monitoring for infusion reactions. Post-infusion monitoring includes vital sign checks and documentation of tolerance; education is provided about expected effects and when to seek care for adverse reactions. Typical sites of service are outpatient infusion centers, hospital outpatient departments, and, less commonly, skilled nursing facilities for patients who require facility-based infusion support.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to prepare or administer the infusion is substantially greater than normally required (document justification). |